GCN2: Roles in Tumour Development and Progression

Overview

Journal Biochem Soc Trans

Specialty Biochemistry

Date 2022 Mar 21

PMID 35311890

Authors

Lyssa T Gold

Glenn R Masson

Affiliations

Soon will be listed here.

Abstract

GCN2 (general control nonderepessible 2) is an eIF2α kinase responsible for entirely rewiring the metabolism of cells when they are put under amino acid starvation stress. Recently, there has been renewed interest in GCN2 as a potential oncotarget, with several studies reporting the development of small molecule inhibitors. The foundation of this work is built upon biochemical and cellular data which suggest GCN2 may be aberrantly overexpressed and is responsible for keeping cells on 'life-support' while tumours undergo significant nutritional stress during tumorigenesis, allowing cancer stem cells to develop chemotherapeutic resistance. However, most studies which have investigated the role of GCN2 in cancer have been conducted in various cancer model systems, often under a specific set of stresses, mutational backgrounds and drug cocktails. This review aims to comprehensively summarise the biochemical, molecular and cellular literature associated with GCN2 and its role in various cancers and determine whether a consensus can be developed to discern under which circumstances we may wish to target GCN2.

Citing Articles

Circadian clock control of interactions between eIF2α kinase CPC-3 and GCN1 with ribosomes regulates rhythmic translation initiation.

Preh E, Ramirez M, Mohan S, Guy C, Bell-Pedersen D Proc Natl Acad Sci U S A. 2025; 122(6):e2411916122.

PMID: 39903114 PMC: 11831163. DOI: 10.1073/pnas.2411916122.

Cellular Signaling of Amino Acid Metabolism in Prostate Cancer.

Yao P, Cao S, Zhu Z, Wen Y, Guo Y, Liang W Int J Mol Sci. 2025; 26(2).

PMID: 39859489 PMC: 11765784. DOI: 10.3390/ijms26020776.

BRAF and ErbB inhibitors directly activate GCN2 in an off-target manner to limit cancer cell proliferation.

Ryland C, Ill C, Marikar N, Nguyen V, Nangia V, Darnell A bioRxiv. 2025; .

PMID: 39763857 PMC: 11702603. DOI: 10.1101/2024.12.19.629301.

The amino-acid stress sensing eIF2α kinase GCN2 is a survival biomarker for malignant mesothelioma.

Gold L, Bray S, Kernohan N, Henderson N, Nowicki M, Masson G BJC Rep. 2024; 1(1):4.

PMID: 39516654 PMC: 11523953. DOI: 10.1038/s44276-023-00004-y.

General control nonderepressible 2 (GCN2) as a therapeutic target in age-related diseases.

Altintas O, MacArthur M Front Aging. 2024; 5:1447370.

PMID: 39319345 PMC: 11420162. DOI: 10.3389/fragi.2024.1447370.

References

Seborova K, Vaclavikova R, Soucek P, Elsnerova K, Bartakova A, cernaj P . Association of ABC gene profiles with time to progression and resistance in ovarian cancer revealed by bioinformatics analyses. Cancer Med. 2019; 8(2):606-616. PMC: 6382717. DOI: 10.1002/cam4.1964. View

Wang S, Chen M, Chou Y, Ueng Y, Yin P, Yeh T . Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway. Oncotarget. 2016; 7(45):74132-74151. PMC: 5342041. DOI: 10.18632/oncotarget.12356. View

Lehman S, Ryeom S, Koumenis C . Signaling through alternative Integrated Stress Response pathways compensates for GCN2 loss in a mouse model of soft tissue sarcoma. Sci Rep. 2015; 5:11781. PMC: 4485314. DOI: 10.1038/srep11781. View

Jin L, Alesi G, Kang S . Glutaminolysis as a target for cancer therapy. Oncogene. 2015; 35(28):3619-25. PMC: 5225500. DOI: 10.1038/onc.2015.447. View

Pathria G, Lee J, Hasnis E, Tandoc K, Scott D, Verma S . Translational reprogramming marks adaptation to asparagine restriction in cancer. Nat Cell Biol. 2019; 21(12):1590-1603. PMC: 7307327. DOI: 10.1038/s41556-019-0415-1. View

Romano P, Zhang X, Wang Q, Taylor D, Zhang F, Herring C . Autophosphorylation in the activation loop is required for full kinase activity in vivo of human and yeast eukaryotic initiation factor 2alpha kinases PKR and GCN2. Mol Cell Biol. 1998; 18(4):2282-97. PMC: 121479. DOI: 10.1128/MCB.18.4.2282. View

Vattem K, Wek R . Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc Natl Acad Sci U S A. 2004; 101(31):11269-74. PMC: 509193. DOI: 10.1073/pnas.0400541101. View

Schmidt S, Gay D, Uthe F, Denk S, Paauwe M, Matthes N . A MYC-GCN2-eIF2α negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer. Nat Cell Biol. 2019; 21(11):1413-1424. PMC: 6927814. DOI: 10.1038/s41556-019-0408-0. View

Kanno A, Asahara S, Furubayashi A, Masuda K, Yoshitomi R, Suzuki E . GCN2 regulates pancreatic β cell mass by sensing intracellular amino acid levels. JCI Insight. 2020; 5(9). PMC: 7253016. DOI: 10.1172/jci.insight.128820. View

10.

Wu C, Peterson A, Zinshteyn B, Regot S, Green R . Ribosome Collisions Trigger General Stress Responses to Regulate Cell Fate. Cell. 2020; 182(2):404-416.e14. PMC: 7384957. DOI: 10.1016/j.cell.2020.06.006. View

11.

Harding H, Ordonez A, Allen F, Parts L, Inglis A, Williams R . The ribosomal P-stalk couples amino acid starvation to GCN2 activation in mammalian cells. Elife. 2019; 8. PMC: 6919976. DOI: 10.7554/eLife.50149. View

12.

Siu F, Bain P, Chen H, Kilberg M . ATF4 is a mediator of the nutrient-sensing response pathway that activates the human asparagine synthetase gene. J Biol Chem. 2002; 277(27):24120-7. DOI: 10.1074/jbc.M201959200. View

13.

Ye J, Kumanova M, Hart L, Sloane K, Zhang H, De Panis D . The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J. 2010; 29(12):2082-96. PMC: 2892366. DOI: 10.1038/emboj.2010.81. View

14.

Qing G, Li B, Vu A, Skuli N, Walton Z, Liu X . ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell. 2012; 22(5):631-44. PMC: 3510660. DOI: 10.1016/j.ccr.2012.09.021. View

15.

Zhang P, McGrath B, Reinert J, Olsen D, Lei L, Gill S . The GCN2 eIF2alpha kinase is required for adaptation to amino acid deprivation in mice. Mol Cell Biol. 2002; 22(19):6681-8. PMC: 134046. DOI: 10.1128/MCB.22.19.6681-6688.2002. View

16.

Cherkasova V, Hinnebusch A . Translational control by TOR and TAP42 through dephosphorylation of eIF2alpha kinase GCN2. Genes Dev. 2003; 17(7):859-72. PMC: 196024. DOI: 10.1101/gad.1069003. View

17.

Ghosh J, Perego M, Agarwal E, Bertolini I, Wang Y, Goldman A . Ghost mitochondria drive metastasis through adaptive GCN2/Akt therapeutic vulnerability. Proc Natl Acad Sci U S A. 2022; 119(8). PMC: 8872753. DOI: 10.1073/pnas.2115624119. View

18.

Tameire F, Verginadis I, Leli N, Polte C, Conn C, Ojha R . ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression. Nat Cell Biol. 2019; 21(7):889-899. PMC: 6608727. DOI: 10.1038/s41556-019-0347-9. View

19.

Jewer M, Lee L, Leibovitch M, Zhang G, Liu J, Findlay S . Translational control of breast cancer plasticity. Nat Commun. 2020; 11(1):2498. PMC: 7237473. DOI: 10.1038/s41467-020-16352-z. View

20.

Zhang F, Zeng Q, Xu H, Xu A, Liu D, Li N . Selective and competitive functions of the AAR and UPR pathways in stress-induced angiogenesis. Cell Discov. 2021; 7(1):98. PMC: 8547220. DOI: 10.1038/s41421-021-00332-8. View